Antihypertensive therapy in patients with diabetes mellitus and chronic kidney disease specifications: the perspective of modern European guidelines 2018

Cover Page

Cite item

Full Text

Abstract

In the present article antihypertensive therapy (AT) properties in patients with type 2 diabetes mellitus and chronic kidney disease are discussed from the perspective of modern European guidelines 2018. Calcium channel blocker nitrendipine and thiazid-like diuretic indapamide place in AT is discussed and their advantages of use in combination therapy in these patients are presented

About the authors

O. D Ostroumova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: ostroumova.olga@mail.ru
р мед. наук, проф. каф. факультетской терапии и профболезней; проф. каф. клинической фармакологии и пропедевтики внутренних болезней; зав. лаб. клинической фармакологии и фармакотерапии 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1; 119991, Russian Federation, Moscow, ul. Trubetskaia d. 8, str. 1

I. V Goloborodova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation - Russian Gerontological Scientific Clinical Center

Email: giv55555@ramler.ru
канд. мед. наук, доц. каф. факультетской терапии и профболезней 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1; 129226, Russian Federation, Moscow, ul. 1-ia Leonova, d. 16

References

  1. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389 (10064): 37-55. doi: 10.1016/S0140-6736(16)31919-5
  2. Chow C.K, Teo K.K, Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310 (9): 959-68. doi: 10.1001/jama.2013.184182
  3. Kearney P.M, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23. doi: 10.1016/S0140-6736(05)70151-3
  4. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; (00): 1-98. doi: 10.1093/eurheartj/ehy339
  5. Forouzanfar M.H, Liu P, Roth G.A et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317 (2): 165-82. doi: 10.1001/jama.2016.19043
  6. Общероссийская общественная организация Ассоциация врачей общей практики (семейных врачей). Секция «Сочетанные патологии». Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваск. терапия и профилактика. 2017; 16 (6): 5-56. doi: 10.15829/1728-8800-2017-6
  7. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 1 (20): 13-41.
  8. IDF Diabetes Atlas, 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetes-atlas/134-idf-diabetes-atlas-8th-edition. html.
  9. Davy K.P, Hall J.E. Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004; 286 (5): 803-13.
  10. Морозова Т.Е. Особенности антигипертензивной терапии у пациентов с метаболическим синдромом и сахарным диабетом. Справочник поликлинического врача. 2006; 8: 25-31.
  11. Kaur J. A comprehensive Review on Metabolic Syndrome. Cardiol Res Practice 2014. DOI: org/10.1155/2014/943162
  12. Samson S.L, Garber A.J. Metabolic syndrome. Endocr Metab Clin North Am 2014; 43 (1): 1-23. PMID: 24582089
  13. Российское медицинское общество по артериальной гипертонии (РМОАГ). Рекомендации по ведению больных метаболическим синдромом. Клинические рекомендации. М., 2013.
  14. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabet Vasc Dis 2013; 4 (13): 192-207. doi: 10.1177/1474651413495703
  15. Sarwar N, Gao P, Seshasai S.R et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22. doi: 10.1016/S0140-6736(10)60484-9
  16. Kannel W.B, McGee D.L. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035-8.
  17. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21 (1): 69-75.
  18. Multiple Risk Factor Intervention Trial Research Group: relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med 1986; 15: 254-73.
  19. Haffner M, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction. N Eng J Med 1998; 339: 229-34.
  20. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. doi: 10.1016/S0140-6736(98)07019-6
  21. Блокаторы кальциевых каналов: описание фармакологической группы в Энциклопедии РЛС. Регистр лекарственных средств России, РЛС. URL: https://www.rlsnet.ru/fg_index_id_215.htm
  22. Fagard R.H, Staessen J.A. Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin Exp Hypertens 1999; 21 (5-6): 491-7. PMID: 10423075
  23. Wang J.G, Staessen J.A, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211-20. PMID: 10647760
  24. Tuomilehto J, Rastenyte D, Birkenhager W.H et al. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. Eng J Med 1999; 340 (9): 677-84.
  25. Farský S, Strišková A, Borčin M. Hypertension Treatment in Patients with Metabolic Syndrome and/or Type 2 Diabetes Mellitus: Analysis of the Therapy Effectivity and the Therapeutic Inertia in Outpatient Study. Card Res Practice 2018; 2018 (1): 8387613. doi: 10.1155/2018/8387613
  26. Rohr G, Reimnitz P, Blanke P. Treatment of hypertensive emergency. Comparison of a new dosage form of the calcium antagonist nitrendipine with nifedipine capsules. Int Care Med 1994; 20 (4): 268-71. PMID: 8046120
  27. Mancini M, Marotta T, Ferrara L.A. Metabolic neutrality in nitrendipine therapy. J Cardiovasc Pharmacol Ther 1991; 18 (1): 3-30.
  28. Ferrara L.A, Marotta T. Nitrendipine and metabolic balance. J Cardiovasc Pharmacol Ther 1991; 18 (5): 19-21.
  29. Grandinetti O, Feraco E. Middle term evaluation of amlodipine vs. nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. Clin Exp hypertens 1993; 15 (1): 197-210. PMID: 8513310
  30. Roush G.C, Ernst M.E, Kostis J.B et al. Head-to-Head Comparisons Hydrochlorothiazide Indapamide and Chlorthalidone: Antihypertensive and Metabolic Effects. Hypertension 2015; 65 (5): 1041-6. doi: 10.1161/hypertensionaha.114.05021
  31. Gerstein H.C, Mann J.F, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286 (4): 421-6. PMID: 11466120
  32. Malhotra R, Nguyen H.A, Benavente O et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. J Am Med Assoc Int Med 2017; 177: 1498-505.
  33. De Zeeuw D, Remuzzi G, Parving H.H et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65 (6): 2309-20.
  34. Voyaki S.M, Staessen J.A, Thijs L et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001; 19 (3): 509-11. PMID: 11288822
  35. Bretzel R.G, Bollen C.C, Maeser E, Federlin K.F. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993; 21 (3): 53-64. PMID: 8503436
  36. Kopf D, Schmitz H, Beyer J et al. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy. Diabetes Nutrition and Metabolism 2001; 14 (5): 245-52. PMID: 11806464
  37. Van Bortel L, Böhm R, Mooy J et al. Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol 1989; 36 (5): 467-71. PMID: 2753064
  38. Aronoff G.R. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects. J Cardiovasc Pharmacol Ther 1984; 6 (7): 974-6. PMID: 6085387
  39. Rahn K.H, Barenbrock M, Fritschka E et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354 (9188): 1415-20. doi: 10.1016/S0140-6736(99)08421-4
  40. Marre M, Garcia Puig J, Kokot F et al. Effect of indapamide SR on microalbuminuria - the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia) - rationale and protocol for the main trial. J Hypertension 2003; 21 (1): 19-24. PMID: 12769163
  41. Марцевич С.Ю., Суханов Я.В., Белолипецкая В.Г., Кутишенко Н.П. Исследование биоэквивалентности как способ доказательства идентичности оригинального препарата и препарата-дженерика. Рос. кардиол. журн. 2005; 2 (52): 76-8. doi: 10.15829/1560-4071-2005-2-76-78
  42. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д., Якусевич В.В. Изучение эффективности и переносимости препарата Индап в сравнении с препаратами Арифон и Арифон ретард у больных мягкой и умеренной артериальной гипертонией, назначаемых как в виде монотерапии, так и в комбинации с ингибиторами АПФ. Многоцентровое, открытое, рандомизированное перекрестное исследование. Рос. кардиол. журн. 2006; 2: 73-7. doi: 10.15829/1560-4071-2006-2-73-77

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies